Training of Ugandans in Basic and Translational Research on TB and Emerging Infectious Diseases

项目总结 在过去的十年里，乌干达的研究基础设施有了很大的扩展，Makerere 位于坎帕拉的墨尔本大学(MU)已成为全球合作的主要学术机构之一 结核病和新发传染病的研究。目前，美国国立卫生研究院、疾控中心、盖茨基金会、惠康信托、 英国医学研究理事会和欧洲和发展中国家临床试验伙伴关系提供 大力支持乌干达的结核病和其他传染病研究，包括评估新的 诊断学；药物治疗方案；疫苗和发病机制及其相关性的翻译研究 豁免权。因此，大多数培训是在临床流行病学和研究设计方面，没有专门的培训。 瞄准实验室研究科学家的缺口，这些科学家将成为教师，具有竞争力 外部资助的研究项目。由于在基础培训和翻译培训方面存在差距 波士顿医学中心(BMC)/波士顿大学学院结核病与新发传染病研究 医学(BUSM)从福格蒂国际中心寻求并获得资金，为产能提供资金 这一地区的建筑。在此期间，三名乌干达科学家在该方案下接受了培训，并 目前正在进修研究生课程。该计划建立了协作联系，巩固了一个联合 承诺由BMC/BUSM和MU共同指导乌干达受训人员。由该基金资助的短期课程 计划已成为硕士和博士生培训方案的关键，并提供了 与教职员工讨论和进一步招聘的渠道。尽管取得了这些进展，但仍有迫切的需要 继续扩大基础研究和翻译研究方面的培训机会。对于此续订申请， 我们将进行两项重大改革。首先，我们将目标对准打算参加 密歇根州立大学博士课程；受训人员将被招募到一个或两个被指定为关键发展领域的地区 墨尔本大学教职员工、项目主任和科学主任。第二，罗格斯-新泽西医疗 学校(NJMS)已被增加为第二个培训地点。它的加入将提供分子方面的专业知识 耐药机制与基础免疫学和翻译免疫学。最重要的是，我们的主要目标是 该计划将为受训人员提供强大的基础研究技能和知识背景，通过 严格的有针对性的课程，加上在特定研究领域的强化实验室培训。我们的 培训计划是针对当前和未来的结核病和新出现的传染病研究而量身定做的 这是穆阿迈尔大学和整个乌干达的需要。

PROJECT SUMMARY The research infrastructure in Uganda has expanded considerably in the last decade and Makerere University (MU) in Kampala has become one of the principal academic institutions worldwide for collaborative research on TB and emerging infectious diseases. Currently NIH, CDC, Gates Foundation, Wellcome Trust, British Medical Research Council and the European & Developing Countries Clinical Trials Partnership provide substantial support for TB and other infectious diseases research in Uganda, including evaluation of new diagnostics; drug treatment regimens; and vaccines and translational studies of pathogenesis and correlates of immunity. As such, most of the training is in clinical epidemiology and study design and none specifically targets the gap in laboratory-based research scientists that will become faculty members, competitive for extramurally funded research programs. Because of identified gaps in training in basic and translational research on TB and emerging infectious diseases, Boston Medical Center (BMC)/Boston University School of Medicine (BUSM) sought out and secured funding from the Fogarty International Center to fund capacity building in this area. During this period, three Ugandan scientists received training under the program and are currently pursuing further graduate studies. The program established collaborative links and solidified a joint commitment to co-mentorship of Uganda trainees by BMC/BUSM and MU. Short courses funded under this program have become essential to the training regimen of masters and PhD students and have provided a conduit for discussion with faculty and further recruitment. Despite these strides, there is still a pressing need to continue to expand training opportunities in basic and translational research. For this renewal application, we will make two significant changes. First, we will target medical school graduates who intend to enroll in a PhD program at MU; trainees will be recruited to one or two areas designated as critical for development by the MU faculty and the Program Directors and Scientific Directors. Second, Rutgers-New Jersey Medical School (NJMS) has been added as a second site of training. Its addition will provide expertise molecular mechanisms of drug resistance and basic and translational immunology. Above all, our main objective of the program will be to provide trainees with a strong background in basic research skills and knowledge through rigorous targeted coursework coupled with intensive laboratory training in a particular research area. Our training program is tailored to address the current and future TB and emerging infectious disease research needs of MU as well as Uganda as a whole.